Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial

Fei Cao, Yan Li, Qi Fang, Ruobin Lin, Zheng Zhao, Pengfei Xu, Honghong Yan, Xinrui Zhang, Ke Jiang, Jian Zhou, Chunyan Chen, Lixia Lu, Fei Han, Zhiming Li, Di Wu, Xuekui LiuClinical 2025 · DOI

Abstract

Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.
BibTeX
@inproceedings{cao2025cadonilimab,
  author = {Fei Cao and Yan Li and Qi Fang and Ruobin Lin and Zheng Zhao and Pengfei Xu and Honghong Yan and Xinrui Zhang and Ke Jiang and Jian Zhou and Chunyan Chen and Lixia Lu and Fei Han and Zhiming Li and Di Wu and Xuekui Liu},
  title = {{Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1078-0432.ccr-25-1445},
}

Loading related content...

Figure